Diversity, Equity and Inclusion:
Celebrating Black History Month with the African American Employee Impact Group
Diversity in Action: Disabilities
Environmental Action Plan
Climate Change Measures
Astellas has adopted the method for setting reduction targets recommended by the Science Based Targets Initiative (SBTi). This method is designed to achieve the 2°C target of the Paris Agreement, which entered into force in 2016.
• Reduce GHG emissions (Scope 1 + Scope 2) by 30% by fiscal 2030 (Base year: fiscal 2015) (Emissions in the base year: 202 kilotons)
• Reduce GHG emissions (Scope 3) by 20% per unit of revenue by fiscal 2030 (Base year: fiscal 2015)
Using Renewable Energy
Access & Affordability:
Access to Health of Astellas
Astellas continues to contribute to the health of patients by researching, developing, and delivering innovative healthcare solutions to address diseases with high unmet medical needs.
(1) Providing VALUE based on science
For patients who are unable to receive appropriate medical care for socioeconomic reasons, we have established a comprehensive Access to Medicine mechanism to enhance the availability of Astellas therapies while taking into consideration the situation and regulations in each country.
(2) Access to Medicines
In addition, Astellas is tackling more diverse issues of Access to Health by collaborating with and supporting the activities of external partners while leveraging our capabilities and technologies.
(3) Collaboration and support for the activities implemented by external partners to improve Access to Health.
Patient Access and Affordability for Astellas Medications in the U.S.
Improving access to medicines requires investment at all stages of the product lifecycle, from early planning and discovery through to clinical research, development and ultimately bringing the therapy to market. We are working to ensure our end-to-end access to medicines strategy influences where we are delivering our therapies.
Astellas Pharma Support Solutions
Astellas Pharma Support Solutions offers access and reimbursement services to help patients and their healthcare providers overcome challenges to accessing Astellas products. The program provides information regarding patient healthcare coverage options and financial assistance programs to help patients with financial needs.
Astellas Pharma Support Solutions is designed as a single point of contact to help patients understand their coverage and reimbursement options when they are prescribed an Astellas medication.
The resource also may assist healthcare providers with navigating a patient’s insurance access and affordability issues through support with Benefits Verification, Prior Authorization, Billing and Coding, Forms and Documents, and patient financial assistance options.
Early Access to Investigational Therapy
As described in our Position on Early Access and Post-Trial Access to Investigational Therapy, Astellas believes the safest and most effective way of providing access to the company's investigational therapies is through enrollment in its ongoing clinical trials.
Astellas also recognizes the importance of utilizing the applicable regulatory and legal pathways for providing access to our investigational therapies when patients with life-threatening diseases have exhausted all available treatment options and are not eligible for clinical trials.
For ongoing clinical trials sponsored by Astellas with investigational therapies currently in development, please visit https://clinicaltrials.gov/.
The Flying Star Fund
The Flying Star Fund, established in 1996 by Astellas’ employee volunteers, is a Matching Gift program which matches employee donations made throughout the year. Through the Flying Star Fund, Astellas provides donations of wheelchair-accessible vans to welfare facilities and nonprofit organizations for children with intractable diseases.